June 2026 in “Precision medicine and engineering.” In this study, researchers created a hydrogel that reduces oxidative stress and releases a pro-angiogenic drug in response to enzyme activity, which accelerated healing and improved tissue regeneration in chronic diabetic wounds during in vivo experiments.
522 citations
,
January 2001 in “Cancer investigation” This review describes the unique pharmacological profile and clinical applications of pegylated liposomal doxorubicin, emphasizing its role in Kaposi's sarcoma and recurrent ovarian cancer, but reports no new clinical results.
4 citations
,
June 2013 in “The Journal of Rheumatology” This abstract describes a program with various presentations and events focused on Canadian excellence in rheumatology but reports no new research findings.
108 citations
,
December 2003 in “Clinical breast cancer” The authors concluded that pegylated liposomal doxorubicin may offer comparable efficacy to conventional doxorubicin with reduced toxicity in metastatic breast cancer treatment.
May 2026 in “AAPS PharmSciTech” This study found that PEGylated LUT-Aspasomes significantly improved neuroprotective effects in stressed rats, enhancing spatial memory, reducing depressive-like behavior, and preserving hippocampal architecture better than free luteolin. Additionally, it increased brain delivery and stability, suggesting potential for treating stress-related neurobehavioral disorders.
